Tau PET/CT in Various Tau-Related Disease Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorTianjin Medical University
About this trial
To evaluate the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
18F-S16/T807
Diagnostic testEach subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
Treatment groups
500 Participants
are divided into 1 treatment groupGroup A: Single Group Assignment1 intervention
Trial outcomes
Primary outcomes
1
Standardized uptake value (SUV)
Standardized uptake value (SUV) of S16/T807 for each target lesion of subject or suspected primary tumor or/and metastasis.
Time frame
30 daysSecondary outcomes
1
Diagnostic efficacy
The sensitivity, specificity and accuracy of Tau PET/CT were calculated.
Time frame
30 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Tianjin Medical University
Lead sponsor
Tianjin Medical University General Hospital
Collaborator
Source ClinicalTrials.gov